Long-term Treatment of Acromegaly with Lanreotide: Evidence of Increased Serum Parathormone Concentration

Endocrine Journal

Barbara AGOSTI¹  Elvira De MARTINO¹  Carlo CAPPELLI¹  Enrico Agabiti ROSEI¹  Ilenia PIROLA¹  Elena GANDOSSI¹  Maurizio CASTELLANO¹  Bruno CERUDELLI¹  Davide CUMETTI¹ 

[1] Internal Medicine, Endocrinology Section, University of Brescia

关键词: Acromegaly;    Lanreotide;    Parathormone;    Bone homeostasis;   

DOI  :  10.1507/endocrj.51.517

学科分类：内分泌与代谢学

来源: Japan Endocrine Society

【 摘 要 】

References(26)Cited-By(7)The somatostatin analogue lanreotide is effective in reducing growth hormone levels in patients with acromegaly. Acromegaly is characterized by calcium homeostasis alterations. The aim of our study was to evaluate the effects of lanreotide on bone turnover markers in a group of acromegalic patients and to verify a possible increase of intact parathormone (iPTH) levels in a transient or persistent way. Serum GH, IGF-I and serum and urinary markers of bone metabolism were measured before treatment and on months 3 and 24. In short-term treatment (3 months), lanreotide significantly decreased GH, IGF-I, serum calcium, osteocalcin and alkaline phosphatase levels, but increased iPTH level (49 ± 16.7 vs pre-treatment 28.3 ± 7.6 ng/L, pvs 28.3 ± 7.6 ng/L, p<0.05). No changes were seen in serum albumin, creatinine and vitamin D during short and long term treatment. The changes of most bone markers during lanreotide treatment can be explained by the decrease of GH and IGF-I. The increase of iPTH concentration suggests that lanreotide has ulterior and long-standing actions on calcium homeostasis: intestinal malabsorption of calcium due to the lanreotide could contribute to this "secondary" hyperparathyroidism. The clinical relevance of these long-standing effects needs to be further investigated.

【 授权许可】

Unknown